Skip to content

Evaluation of a a weight management program for young people

Evaluation of a 12 week commercial weight management program for adolescents

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN13602313
Enrollment
140
Registered
2013-04-10
Start date
2013-03-18
Completion date
Unknown
Last updated
2020-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight and obesity in adolescents Nutritional, Metabolic, Endocrine Obesity

Interventions

The intervention group will engage in the 12 week JenMe program, whereas the wait-listed group will delay their enrolment for 12 weeks.

Sponsors

Monash University (Australia)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Adolescents seeking weight management aged 13 to 17 years 2. BMI z-score ? 1.282 3. Available to complete the 12 week program in a maximum of 14 weeks

Exclusion criteria

Exclusion criteria: 1. Less than 13 years of age 2. Over 17 years and 2 months of age at time of commencement in study 3. Pregnant or breastfeeding 4. A health condition - Adolescents joining the Jenny Craig program are screened by a company doctor and a health checklist completed. Potential clients are not permitted to enrol in the program if they have a health condition that that requires medication or ongoing health screening. If necessary, the company doctor will liaise between the company and the potential client's GP in order to ascertain medical history and thus advise Jenny Craig as to an individual's suitability to join the program.

Design outcomes

Primary

MeasureTime frame
1. Change in body mass index z-score 2. Change in weight to height ratio Measured at baseline, 12 weeks and nine months from baseline

Secondary

MeasureTime frame
1. Change in activity levels will be measured using pedometers and an activity diary 2. Change in behaviour and self esteem will be measured using validated questionnaires 3. Changes in body composition will be measured using DXA 4. Changes in cardiometabolic risk factors in blood plasma will be measured in blood and will include fasting glucose, triacylglycerols and cholesterol

Countries

Australia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 10, 2026